Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response

Rachael P. Jackman, Xutao Deng, Douglas Bolgiano, Garth H Utter, Cathy Schechterly, Mila Lebedeva, Eva Operskalski, Naomi L. Luban, Harvey Alter, Michael P. Busch, Sherrill J. Slichter, Philip J. Norris

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear. Study Design and Methods Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence. Results Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed Class II HLA antibodies compared with 28% (Class I) and 15% (Class II) for those receiving leukoreduced blood and 36% (Class I) and 54% (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies. Conclusions These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.

Original languageEnglish (US)
Pages (from-to)672-680
Number of pages9
JournalTransfusion
Volume54
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Antibody Formation
Antibodies
Incidence
Ultraviolet Rays
Cohort Studies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology
  • Immunology

Cite this

Jackman, R. P., Deng, X., Bolgiano, D., Utter, G. H., Schechterly, C., Lebedeva, M., ... Norris, P. J. (2014). Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion, 54(3), 672-680. https://doi.org/10.1111/trf.12317

Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. / Jackman, Rachael P.; Deng, Xutao; Bolgiano, Douglas; Utter, Garth H; Schechterly, Cathy; Lebedeva, Mila; Operskalski, Eva; Luban, Naomi L.; Alter, Harvey; Busch, Michael P.; Slichter, Sherrill J.; Norris, Philip J.

In: Transfusion, Vol. 54, No. 3, 2014, p. 672-680.

Research output: Contribution to journalArticle

Jackman, RP, Deng, X, Bolgiano, D, Utter, GH, Schechterly, C, Lebedeva, M, Operskalski, E, Luban, NL, Alter, H, Busch, MP, Slichter, SJ & Norris, PJ 2014, 'Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response', Transfusion, vol. 54, no. 3, pp. 672-680. https://doi.org/10.1111/trf.12317
Jackman, Rachael P. ; Deng, Xutao ; Bolgiano, Douglas ; Utter, Garth H ; Schechterly, Cathy ; Lebedeva, Mila ; Operskalski, Eva ; Luban, Naomi L. ; Alter, Harvey ; Busch, Michael P. ; Slichter, Sherrill J. ; Norris, Philip J. / Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. In: Transfusion. 2014 ; Vol. 54, No. 3. pp. 672-680.
@article{e489e63ab8af41a999ad93bc8de5ae3c,
title = "Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response",
abstract = "Background Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear. Study Design and Methods Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence. Results Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55{\%} developed Class I HLA antibodies and 51{\%} developed Class II HLA antibodies compared with 28{\%} (Class I) and 15{\%} (Class II) for those receiving leukoreduced blood and 36{\%} (Class I) and 54{\%} (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies. Conclusions These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.",
author = "Jackman, {Rachael P.} and Xutao Deng and Douglas Bolgiano and Utter, {Garth H} and Cathy Schechterly and Mila Lebedeva and Eva Operskalski and Luban, {Naomi L.} and Harvey Alter and Busch, {Michael P.} and Slichter, {Sherrill J.} and Norris, {Philip J.}",
year = "2014",
doi = "10.1111/trf.12317",
language = "English (US)",
volume = "54",
pages = "672--680",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response

AU - Jackman, Rachael P.

AU - Deng, Xutao

AU - Bolgiano, Douglas

AU - Utter, Garth H

AU - Schechterly, Cathy

AU - Lebedeva, Mila

AU - Operskalski, Eva

AU - Luban, Naomi L.

AU - Alter, Harvey

AU - Busch, Michael P.

AU - Slichter, Sherrill J.

AU - Norris, Philip J.

PY - 2014

Y1 - 2014

N2 - Background Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear. Study Design and Methods Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence. Results Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed Class II HLA antibodies compared with 28% (Class I) and 15% (Class II) for those receiving leukoreduced blood and 36% (Class I) and 54% (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies. Conclusions These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.

AB - Background Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear. Study Design and Methods Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence. Results Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed Class II HLA antibodies compared with 28% (Class I) and 15% (Class II) for those receiving leukoreduced blood and 36% (Class I) and 54% (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies. Conclusions These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.

UR - http://www.scopus.com/inward/record.url?scp=84896037606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896037606&partnerID=8YFLogxK

U2 - 10.1111/trf.12317

DO - 10.1111/trf.12317

M3 - Article

C2 - 23808544

AN - SCOPUS:84896037606

VL - 54

SP - 672

EP - 680

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 3

ER -